CLL3 trial: multivariate prognostic factor analysis (Cox backward; n = 121)
| End point . | Variable . | P . | HR . | Lower CL . | Upper CL . |
|---|---|---|---|---|---|
| PFS | 17p- | < .001 | 19.08 | 5.53 | 65.83 |
| IGHV unfavorable | < .001 | 3.35 | 1.87 | 5.99 | |
| OS | 17p- | < .001 | 8.35 | 2.56 | 27.22 |
| IGHV unfavorable | .006 | 3.11 | 1.37 | 7.02 | |
| Binet stage B | .076 | 6.12 | 0.83 | 45.29 | |
| Binet stage C | .025 | 10.25 | 1.33 | 78.98 | |
| Age (/y) | .067 | 1.047 | 0.997 | 1.099 |
| End point . | Variable . | P . | HR . | Lower CL . | Upper CL . |
|---|---|---|---|---|---|
| PFS | 17p- | < .001 | 19.08 | 5.53 | 65.83 |
| IGHV unfavorable | < .001 | 3.35 | 1.87 | 5.99 | |
| OS | 17p- | < .001 | 8.35 | 2.56 | 27.22 |
| IGHV unfavorable | .006 | 3.11 | 1.37 | 7.02 | |
| Binet stage B | .076 | 6.12 | 0.83 | 45.29 | |
| Binet stage C | .025 | 10.25 | 1.33 | 78.98 | |
| Age (/y) | .067 | 1.047 | 0.997 | 1.099 |
Covariates considered for all end points were 17p- vs other karyotypes; IGHV unfavorable vs favorable; Binet stage A, B, C; leukocyte count > 50/nL vs less; sex; cytoreductive regimen (FC, F, CHOP, none); and age. Only covariates remaining in the final models are listed.
HR indicates hazard ratio.